Drug Research
Aimmune secures $200m funding from Nestle Health Science
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in...
Drug Research
Grey Wolf completes £2.5m Series A2 financing for development of therapies targeting ERAP2
Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno-oncology (IO), announces it has completed a £2.5 million ($3.3 million) Series A2 financing round with existing leading international healthcare investors Andera Partners and Canaan.
The...
Drug Research
New Velesco Pharma clinical manufacturing facility begins operations
Pharmaceutical development expert, Velesco Pharma, is initiating operations at its new state-of-the-art cGMP clinical manufacturing facility in Wixom, Michigan.
Set to triple the company’s cGMP clinical trial manufacturing capacity, the newly renovated building will feature expanded processing suite space to...
Drug Research
Eisai’s DAYVIGO gets approval in Japan to treat insomnia
Eisai Co., Ltd. announced that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia.
DAYVIGO is a dual orexin receptor antagonist...
Drug Research
Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc
Eisai Co., Ltd. announced that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research.
In this joint research and development, Eisai and...
Drug Research
Medigene, IRICoR and Universite de Montreal sign collaboration and exclusive licensing option on novel cancer antigens
Medigene AG , a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that it has entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with the Universite de Montreal (UdeM) and...
Drug Research
Predictive Oncology Acquire Quantitative Medicine and an AI Engine that Facilitates Accelerated Drug Discovery and Development
Predictive Oncology Inc , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, announces it has signed a letter of intent to acquire Quantitative Medicine.
Dr. Carl Schwartz, president and CEO of Predictive Oncology, believes...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
